Search results
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 7 hours agoNovavax. Last year, Novavax lost $5.41 per share and had $983.7 million in sales. This year, Wall...
FDA advises Covid vaccine makers to target KP.2 for fall shots
NBC News via Yahoo News· 3 hours agoThe FDA advised drugmakers to update Covid vaccines to target the KP.2 strain, a descendant of the...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 6 hours agoWho should wait, and who should get vaccinated now? The CDC advises that everyone ages 5 and older...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 8 hours agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 10 hours agoCases are “stable or uncertain” in 18 others and are likely declining in one—Oklahoma. Do Vaccines...
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks via Yahoo Finance· 4 days agoZacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing...
New COVID Vaccines Targeting JN.1 Will Arrive This Fall
Verywell Health via Yahoo News· 6 days agoA non-mRNA vaccine option is important for the fall rollout, Jetelina said, especially since some...
Two shots in one? Moderna's COVID-19 and flu vaccine reports favorable results
USA Today· 4 days agoModerna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune...
FDA tells Covid-19 vaccine makers to update shot to target current virus variant
WKBT La Crosse· 6 days agoThe FDA’s committee of independent advisers voted unanimously Wednesday to recommend that the agency...
Healthy Returns: What we know about the next round of Covid vaccines
CNBC· 1 day agoA new round of Covid shots will likely reach Americans in the coming months. Here's what we know...